Updated:
FAScinate Therapeutics
FAScinate Therapeutics is developing KM-819, a drug candidate to halt Parkinson's disease progression, operating from New York and San Diego.
FAScinate Therapeutics
Fascinate Therapeutics is a biotechnology company founded in 2018 in San Diego, California. The company is developing KM-819, a treatment intended to slow or halt neurodegenerative diseases such as Parkinson's disease and multiple system atrophy. Fascinate Therapeutics is currently in clinical development of KM-819 and seeks partnerships for investment or development.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
San Diego, CA, United States
Sector focus
Frequently asked questions
Who makes investment decisions at FAScinate Therapeutics?
The firm does not publicly name its investment committee or decision-makers. Its website lists no executive team, board, or advisors (per firm website).
How does FAScinate Therapeutics source its drug candidate?
KM-819 was developed internally or in-licensed. The firm does not disclose the origin of the asset or any prior corporate or academic partnerships (per firm website).
Is FAScinate Therapeutics a single-family office or a drug development company?
The firm presents itself as a therapeutics company. No disclosures indicate it manages outside capital or functions as a multi-family office. Its status as a family office is inferred from its classification in external databases.
Does FAScinate Therapeutics invest in other companies or funds?
No. The firm's sole disclosed activity is developing KM-819. It does not report investments in other biotech, venture funds, or any other asset classes (per firm website).
What clinical stage is KM-819 in?
The firm states KM-819 is in clinical development but does not specify the phase on its website. No trial registrations or regulatory filings are linked from the site.
What neurodegenerative conditions does KM-819 target?
KM-819 is being developed for Parkinson's disease and multiple system atrophy, both progressive conditions without approved disease-modifying therapies (per firm website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: